Metabolic reallocation in spinal cord oligodendrocytes drives chronic pain in mice through neuronal Aβ42 production

IF 15.6 1区 医学 Q1 CELL BIOLOGY
Yannick Fotio, Saeed Al Masri, Zechuan Shi, Johnny Le, Sudeshna Das, Varvara I. Rubtsova, Alex Mabou Tagne, Cholsoon Jang, Vivek Swarup, Daniele Piomelli
{"title":"Metabolic reallocation in spinal cord oligodendrocytes drives chronic pain in mice through neuronal Aβ42 production","authors":"Yannick Fotio,&nbsp;Saeed Al Masri,&nbsp;Zechuan Shi,&nbsp;Johnny Le,&nbsp;Sudeshna Das,&nbsp;Varvara I. Rubtsova,&nbsp;Alex Mabou Tagne,&nbsp;Cholsoon Jang,&nbsp;Vivek Swarup,&nbsp;Daniele Piomelli","doi":"10.1126/scitranslmed.aea8738","DOIUrl":null,"url":null,"abstract":"<div >Recent evidence implicates a metabolic switch in afferent spinal circuits as a key driver of the transition from acute pain– to chronic pain–related behaviors in mice after tissue injury, yet the cellular substrates and functional consequences remain incompletely defined. Using a combination of pharmacological and genetic approaches, we investigated whether metabolic reprogramming in spinal cord cell populations constitutes a causal mechanism linking peripheral injury to the progression to pain chronicity. After peripheral injury induced by a hindpaw formalin injection in mice, single-nucleus RNA sequencing (snRNA-seq) revealed that spinal oligodendrocytes down-regulated transcripts for myelin protein synthesis and up-regulated transcripts important for lipid biosynthesis. Comparative lipidomics showed that this resource reallocation after peripheral injury was associated with disrupted spinal myelin composition. Moreover, axonal integrity was compromised, causing neuronal accumulation of amyloid precursor protein, enhanced β-site amyloid precursor protein–cleaving enzyme 1 (BACE1) expression, and increased insoluble amyloid-β<sub>42</sub> (Aβ<sub>42</sub>) during a critical temporal window for the transition to pain chronicity. Blocking Aβ<sub>42</sub> production by BACE1 inhibition or clearing Aβ<sub>42</sub> by intrathecal 4G8 monoclonal antibody injection prevented the emergence of persistent pain after hindpaw formalin injection. Oligodendrocyte-specific deletion of <i>N</i>-acylethanolamine acid amidase, a key regulator of cell metabolism and pain, prevented Aβ<sub>42</sub> release and chronic pain development induced by formalin injection or sciatic nerve ligation. These findings uncover an unexpected mechanistic link between chronic pain and amyloid pathology and identify the NAAA→Aβ<sub>42</sub> pathway as a target for disease-modifying intervention.</div>","PeriodicalId":21580,"journal":{"name":"Science Translational Medicine","volume":"18 865","pages":""},"PeriodicalIF":15.6000,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.science.org/doi/reader/10.1126/scitranslmed.aea8738","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Science Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.science.org/doi/10.1126/scitranslmed.aea8738","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Recent evidence implicates a metabolic switch in afferent spinal circuits as a key driver of the transition from acute pain– to chronic pain–related behaviors in mice after tissue injury, yet the cellular substrates and functional consequences remain incompletely defined. Using a combination of pharmacological and genetic approaches, we investigated whether metabolic reprogramming in spinal cord cell populations constitutes a causal mechanism linking peripheral injury to the progression to pain chronicity. After peripheral injury induced by a hindpaw formalin injection in mice, single-nucleus RNA sequencing (snRNA-seq) revealed that spinal oligodendrocytes down-regulated transcripts for myelin protein synthesis and up-regulated transcripts important for lipid biosynthesis. Comparative lipidomics showed that this resource reallocation after peripheral injury was associated with disrupted spinal myelin composition. Moreover, axonal integrity was compromised, causing neuronal accumulation of amyloid precursor protein, enhanced β-site amyloid precursor protein–cleaving enzyme 1 (BACE1) expression, and increased insoluble amyloid-β42 (Aβ42) during a critical temporal window for the transition to pain chronicity. Blocking Aβ42 production by BACE1 inhibition or clearing Aβ42 by intrathecal 4G8 monoclonal antibody injection prevented the emergence of persistent pain after hindpaw formalin injection. Oligodendrocyte-specific deletion of N-acylethanolamine acid amidase, a key regulator of cell metabolism and pain, prevented Aβ42 release and chronic pain development induced by formalin injection or sciatic nerve ligation. These findings uncover an unexpected mechanistic link between chronic pain and amyloid pathology and identify the NAAA→Aβ42 pathway as a target for disease-modifying intervention.
脊髓少突胶质细胞的代谢再分配通过神经元Aβ 42的产生驱动小鼠慢性疼痛
最近的证据表明,脊髓传入回路中的代谢转换是组织损伤后小鼠从急性疼痛到慢性疼痛相关行为转变的关键驱动因素,但细胞底物和功能后果仍未完全确定。使用药理学和遗传学方法的结合,我们研究了脊髓细胞群中的代谢重编程是否构成将外周损伤与疼痛慢性进展联系起来的因果机制。小鼠后爪注射福尔马林诱导外周损伤后,单核RNA测序(snRNA-seq)显示,脊髓少突胶质细胞下调髓磷脂蛋白合成转录物,上调脂质生物合成重要转录物。比较脂质组学显示外周损伤后的这种资源再分配与脊髓髓磷脂成分的破坏有关。此外,轴突完整性受损,导致淀粉样蛋白前体蛋白的神经元积累,β位点淀粉样蛋白前体蛋白切割酶1 (BACE1)表达增强,不溶性淀粉样蛋白-β 42 (a β 42)增加,这是向慢性疼痛过渡的关键时间窗口。通过抑制BACE1或鞘内注射4G8单克隆抗体清除Aβ 42,可防止后爪注射福尔马林后出现持续性疼痛。N -酰基乙醇胺酸酰胺酶是细胞代谢和疼痛的关键调节因子,寡突胶质细胞特异性缺失可阻止a β 42的释放和福尔马林注射或坐骨神经结扎引起的慢性疼痛的发展。这些发现揭示了慢性疼痛和淀粉样蛋白病理之间意想不到的机制联系,并确定了NAAA→a β 42通路作为疾病改善干预的靶标。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Science Translational Medicine
Science Translational Medicine CELL BIOLOGY-MEDICINE, RESEARCH & EXPERIMENTAL
CiteScore
26.70
自引率
1.20%
发文量
309
审稿时长
1.7 months
期刊介绍: Science Translational Medicine is an online journal that focuses on publishing research at the intersection of science, engineering, and medicine. The goal of the journal is to promote human health by providing a platform for researchers from various disciplines to communicate their latest advancements in biomedical, translational, and clinical research. The journal aims to address the slow translation of scientific knowledge into effective treatments and health measures. It publishes articles that fill the knowledge gaps between preclinical research and medical applications, with a focus on accelerating the translation of knowledge into new ways of preventing, diagnosing, and treating human diseases. The scope of Science Translational Medicine includes various areas such as cardiovascular disease, immunology/vaccines, metabolism/diabetes/obesity, neuroscience/neurology/psychiatry, cancer, infectious diseases, policy, behavior, bioengineering, chemical genomics/drug discovery, imaging, applied physical sciences, medical nanotechnology, drug delivery, biomarkers, gene therapy/regenerative medicine, toxicology and pharmacokinetics, data mining, cell culture, animal and human studies, medical informatics, and other interdisciplinary approaches to medicine. The target audience of the journal includes researchers and management in academia, government, and the biotechnology and pharmaceutical industries. It is also relevant to physician scientists, regulators, policy makers, investors, business developers, and funding agencies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书